Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study Charles Kyung Min Lee, BS, Shufeng Li, MS, Duy Cong Tran, BS, Gefei Alex Zhu, MD, Jinah Kim, MD, PhD, Bernice Y. Kwong, MD, Anne Lynn S. Chang, MD Journal of the American Academy of Dermatology Volume 79, Issue 6, Pages 1047-1052 (December 2018) DOI: 10.1016/j.jaad.2018.05.035 Copyright © 2018 Terms and Conditions
Fig 1 Oncologic outcomes of patients with and without programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitor–associated dermatitis. A, Kaplan-Meier curves show progression-free survival after initiation of PD-1/PD-L1 inhibitor treatment. Patients who developed a PD-1/PD-L1 inhibitor–associated dermatitis (cases patients [blue]) had significantly longer progression-free survival than did patients with no PD-1/PD-L1 inhibitor–associated dermatitis (controls [red]) (P < .0001). B, Kaplan-Meier curves show overall survival after initiation of PD- 1/PD-L1 inhibitor treatment. Patients who developed a PD-1/PDL1 inhibitor–associated dermatitis (case patients [blue]) had significantly longer overall survival than did patients with no PD-1/PD-L1 inhibitor–associated dermatitis (controls [red]) (P = .0203). Journal of the American Academy of Dermatology 2018 79, 1047-1052DOI: (10.1016/j.jaad.2018.05.035) Copyright © 2018 Terms and Conditions